Clinical stage drug development company Evgen Pharma, which has operations in Liverpool, has been granted a European patent which will complement similar agreements in the US, Canada and Australia.
Under the terms of the deal, intellectual property rights have been ascribed to the company for a method of stabilising sulforaphane; the naturally occurring compound on which its SFX-01 lead product is based.
The grant, which expires on 23 January 2028, marks “another important step” in expanding Evgen’s worldwide intellectual property estate surrounding sulforaphane and represents its second process patent grant in Europe.
Steve Franklin, chief executive of Evgen Pharma, said: “‘We are delighted by the grant of this core patent in Europe, which further expands our intellectual property position and complements similar grants in the USA, Canada and Australia.
“This patent grant is timely from a commercial perspective as we are moving close to the announcement of our first phase II clinical data from SFX-01, which we continue to expect in the first half of this year as part of our ongoing STEM trial in breast cancer.”